A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia
Lu AF11167 is a selective, high-affinity inhibitor of PDE10A that modulates dopamine D1 and D2 receptor-mediated intraneuronal signalling without binding to these receptors. This randomized, double-blind, parallel-group, placebo-controlled study (NCT03793712) with open-label extension (NCT03929497)...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
12 June 2022
|
| In: |
European neuropsychopharmacology
Year: 2022, Jahrgang: 61, Pages: 4-14 |
| ISSN: | 1873-7862 |
| DOI: | 10.1016/j.euroneuro.2022.05.009 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.euroneuro.2022.05.009 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0924977X22002097 
|
| Verfasserangaben: | Andreas Meyer-Lindenberg, Jacob Nielsen, Pedro Such, Ole Michael Lemming, Janos Zambori, Raimund Buller, Christoph von der Goltz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1813242100 | ||
| 003 | DE-627 | ||
| 005 | 20240416193942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220804s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2022.05.009 |2 doi | |
| 035 | |a (DE-627)1813242100 | ||
| 035 | |a (DE-599)KXP1813242100 | ||
| 035 | |a (OCoLC)1361713543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Meyer-Lindenberg, Andreas |d 1965- |e VerfasserIn |0 (DE-588)1029137390 |0 (DE-627)732483069 |0 (DE-576)376589876 |4 aut | |
| 245 | 1 | 2 | |a A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia |c Andreas Meyer-Lindenberg, Jacob Nielsen, Pedro Such, Ole Michael Lemming, Janos Zambori, Raimund Buller, Christoph von der Goltz |
| 264 | 1 | |c 12 June 2022 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.08.2022 | ||
| 520 | |a Lu AF11167 is a selective, high-affinity inhibitor of PDE10A that modulates dopamine D1 and D2 receptor-mediated intraneuronal signalling without binding to these receptors. This randomized, double-blind, parallel-group, placebo-controlled study (NCT03793712) with open-label extension (NCT03929497) evaluated the efficacy of two fixed-flexible doses (1-2mg/day and 3-4mg/day) of Lu AF11167 in stable, non-acute patients with schizophrenia and persistent prominent negative symptoms. The studies were discontinued following a futility analysis of the double-blind study, and we report data collected up to study termination. Of the 210 patients screened, 162 were randomized, 111 completed the double-blind study and 96 entered the open-label study before early termination. The withdrawal rate due to impending relapse was low and comparable across treatment groups (n = 2-4 per group in the double-blind study and n = 1 in the open-label extension). Double-blind treatment with Lu AF11167 3-4mg was not superior to placebo in the reduction of Brief Negative Symptom Scale (BNSS) total scores from Baseline to Week 12 (primary endpoint); adjusted mean changes were -6.8 with placebo, -5.7 with Lu AF11167 1-2 mg group and -6.0 with Lu AF11167 3-4mg. Treatment with Lu AF11167 1-2mg also failed to separate from placebo on the primary endpoint. Neither dose group showed significant improvements versus placebo on any of the secondary efficacy measures exploring effect of treatment on overall symptomology, negative symptoms, positive symptoms, or functioning. Administration of Lu AF11167 was safe and well tolerated and adverse events were not a major reason for withdrawal from the study. | ||
| 650 | 4 | |a Lu AF11167 | |
| 650 | 4 | |a Negative symptoms | |
| 650 | 4 | |a PDE10A | |
| 650 | 4 | |a Phosphodiesterase 10A | |
| 650 | 4 | |a Schizophrenia | |
| 700 | 1 | |a Nielson Arendt, Jacob |d 1973- |e VerfasserIn |0 (DE-588)129915661 |0 (DE-627)483143049 |0 (DE-576)297901141 |4 aut | |
| 700 | 1 | |a Such, Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lemming, Ole Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zambori, Janos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Buller, Raimund |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goltz, Christoph von der |e VerfasserIn |0 (DE-588)1093866780 |0 (DE-627)853885923 |0 (DE-576)462775747 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology |d Amsterdam : Elsevier, 1990 |g 61(2022), Seite 4-14 |h Online-Ressource |w (DE-627)320594025 |w (DE-600)2019305-1 |w (DE-576)266224334 |x 1873-7862 |7 nnas |a A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g pages:4-14 |g extent:11 |a A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.euroneuro.2022.05.009 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0924977X22002097 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220804 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1029137390 |a Meyer-Lindenberg, Andreas |m 1029137390:Meyer-Lindenberg, Andreas |d 60000 |e 60000PM1029137390 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1813242100 |e 4175822836 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1016/j.euroneuro.2022.05.009"],"eki":["1813242100"]},"name":{"displayForm":["Andreas Meyer-Lindenberg, Jacob Nielsen, Pedro Such, Ole Michael Lemming, Janos Zambori, Raimund Buller, Christoph von der Goltz"]},"physDesc":[{"extent":"11 S."}],"recId":"1813242100","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 04.08.2022"],"title":[{"title":"A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia","title_sort":"double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia"}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"12 June 2022"}],"person":[{"display":"Meyer-Lindenberg, Andreas","family":"Meyer-Lindenberg","role":"aut","given":"Andreas"},{"given":"Jacob","role":"aut","family":"Nielson Arendt","display":"Nielson Arendt, Jacob"},{"display":"Such, Pedro","family":"Such","given":"Pedro","role":"aut"},{"display":"Lemming, Ole Michael","family":"Lemming","role":"aut","given":"Ole Michael"},{"display":"Zambori, Janos","given":"Janos","role":"aut","family":"Zambori"},{"display":"Buller, Raimund","family":"Buller","given":"Raimund","role":"aut"},{"given":"Christoph von der","role":"aut","family":"Goltz","display":"Goltz, Christoph von der"}],"relHost":[{"title":[{"title":"European neuropsychopharmacology","title_sort":"European neuropsychopharmacology","subtitle":"ENP ; the journal of the European College of Neuropsychopharmacology"}],"note":["Gesehen am 31.01.20"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1990","publisherPlace":"Amsterdam","dateIssuedDisp":"1990-","publisher":"Elsevier"}],"disp":"A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophreniaEuropean neuropsychopharmacology","recId":"320594025","physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"61(2022), Seite 4-14","volume":"61","extent":"11","pages":"4-14","year":"2022"},"id":{"eki":["320594025"],"issn":["1873-7862"],"zdb":["2019305-1"]},"titleAlt":[{"title":"ENP"}],"pubHistory":["1.1990/91 -"]}]} | ||
| SRT | |a MEYERLINDEDOUBLEBLIN1220 | ||